COX-2, NSAIDs, and cardiovascular risk

Patricia McGettigan; David Henry

doi:10.1007/s12170-007-0048-y

COX-2, NSAIDs, and cardiovascular risk

Patricia McGettigan^*, David Henry

^*Corresponding author for this work

Research output: Contribution to journal › Article › Research › peer-review

Abstract

Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

Original language	English
Pages (from-to)	296-302
Number of pages	7
Journal	Current Cardiovascular Risk Reports
Volume	1
Issue number	4
DOIs	https://doi.org/10.1007/s12170-007-0048-y
Publication status	Published - 2007
Externally published	Yes

Access to Document

10.1007/s12170-007-0048-y

Cite this

@article{f19ebde9651e4ebe853e76aee7e5c433,

title = "COX-2, NSAIDs, and cardiovascular risk",

abstract = "Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.",

author = "Patricia McGettigan and David Henry",

year = "2007",

doi = "10.1007/s12170-007-0048-y",

language = "English",

volume = "1",

pages = "296--302",

journal = "Current Cardiovascular Risk Reports",

issn = "1932-9520",

publisher = "Current Medicine Group",

number = "4",

}

TY - JOUR

T1 - COX-2, NSAIDs, and cardiovascular risk

AU - McGettigan, Patricia

AU - Henry, David

PY - 2007

Y1 - 2007

N2 - Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

AB - Clinical studies of selective and nonselective inhibitors of cyclooxygenase-2 (COX-2) provide evidence that inhibition of the enzyme is associated with modestly increased risks of cardiovascular thrombotic events. Investigation of the physiology of COX-2 demonstrates a complex array of interlinked factors affecting its regulation and function. Efficient integration of data from the basic sciences and randomized and observational studies is necessary to fully understand the consequences of COX-2 inhibition and thereby provide guidance for the safe use of COX-2-inhibiting drugs.

UR - http://www.scopus.com/inward/record.url?scp=84873491701&partnerID=8YFLogxK

U2 - 10.1007/s12170-007-0048-y

DO - 10.1007/s12170-007-0048-y

M3 - Article

AN - SCOPUS:84873491701

SN - 1932-9520

VL - 1

SP - 296

EP - 302

JO - Current Cardiovascular Risk Reports

JF - Current Cardiovascular Risk Reports

IS - 4

ER -

COX-2, NSAIDs, and cardiovascular risk

Abstract

Access to Document

Other files and links

Fingerprint

Cite this